CA1243297A - Crystalline modification of ceftazidim - Google Patents
Crystalline modification of ceftazidimInfo
- Publication number
- CA1243297A CA1243297A CA000452042A CA452042A CA1243297A CA 1243297 A CA1243297 A CA 1243297A CA 000452042 A CA000452042 A CA 000452042A CA 452042 A CA452042 A CA 452042A CA 1243297 A CA1243297 A CA 1243297A
- Authority
- CA
- Canada
- Prior art keywords
- crystalline
- carboxyprop
- aminothiazol
- cephem
- carboxylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000004048 modification Effects 0.000 title description 2
- 238000012986 modification Methods 0.000 title description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims abstract 4
- 208000035143 Bacterial infection Diseases 0.000 claims abstract 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 150000004686 pentahydrates Chemical class 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 238000005169 Debye-Scherrer Methods 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000008642 heat stress Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- ZXIYZDSEASMXPI-UHFFFAOYSA-N 2-(methylamino)ethane-1,1,1-triol Chemical compound CNCC(O)(O)O ZXIYZDSEASMXPI-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229910017488 Cu K Inorganic materials 0.000 description 1
- 229910017541 Cu-K Inorganic materials 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101150054830 S100A6 gene Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229940008015 lithium carbonate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19833313816 DE3313816A1 (de) | 1983-04-16 | 1983-04-16 | Neue kristallmodifikation von ceftazidim |
| DEP3313816.8 | 1983-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1243297A true CA1243297A (en) | 1988-10-18 |
Family
ID=6196559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000452042A Expired CA1243297A (en) | 1983-04-16 | 1984-04-13 | Crystalline modification of ceftazidim |
Country Status (11)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3313818A1 (de) * | 1983-04-16 | 1984-10-18 | Hoechst Ag, 6230 Frankfurt | Neue kristallmodifikation von ceftazidim |
| DE3313816A1 (de) * | 1983-04-16 | 1984-10-18 | Hoechst Ag, 6230 Frankfurt | Neue kristallmodifikation von ceftazidim |
| US4537959A (en) * | 1984-03-26 | 1985-08-27 | Eli Lilly And Company | Crystalline cephalosporin antibiotic salt |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4054738A (en) * | 1975-12-22 | 1977-10-18 | Eli Lilly And Company | Sodium cefamandole crystalline forms |
| AR229883A1 (es) * | 1978-05-26 | 1983-12-30 | Glaxo Group Ltd | Procedimiento para la preparacion de antibiotico(6r,7r)-7-((z)-2-(2-aminotiazol-4-il)-2-(2-carboxiprop-2-oxiimino)-acetamido)-3-(1-piridinometil)-cef-3-em-4-carboxilato |
| DE3037104C2 (de) * | 1979-10-02 | 1986-04-30 | Glaxo Group Ltd., London | Kristallines Bishydrochlorid von (6R,7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(2-carboxyprop-2-oximino)acetamido]-3-(1-pyridiniummethyl)ceph-3-em-4-carboxylat |
| US4329453A (en) * | 1979-10-02 | 1982-05-11 | Glaxo Group Limited | Cephalosporin antibiotic |
| DE3313816A1 (de) * | 1983-04-16 | 1984-10-18 | Hoechst Ag, 6230 Frankfurt | Neue kristallmodifikation von ceftazidim |
-
1983
- 1983-04-16 DE DE19833313816 patent/DE3313816A1/de not_active Withdrawn
-
1984
- 1984-02-28 DK DK120084A patent/DK120084A/da not_active Application Discontinuation
- 1984-04-10 EP EP84103976A patent/EP0122584A3/de not_active Withdrawn
- 1984-04-13 GR GR74414A patent/GR81981B/el unknown
- 1984-04-13 GR GR74413A patent/GR81980B/el unknown
- 1984-04-13 PT PT78419A patent/PT78419B/pt not_active IP Right Cessation
- 1984-04-13 CA CA000452042A patent/CA1243297A/en not_active Expired
- 1984-04-13 ES ES531583A patent/ES8501768A1/es not_active Expired
- 1984-04-13 ZA ZA842775A patent/ZA842775B/xx unknown
- 1984-04-14 KR KR1019840001985A patent/KR910004300B1/ko not_active Expired
- 1984-04-16 AU AU26858/84A patent/AU571507B2/en not_active Ceased
- 1984-04-16 JP JP59076422A patent/JPS59199689A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES531583A0 (es) | 1984-12-01 |
| DK120084D0 (da) | 1984-02-28 |
| AU571507B2 (en) | 1988-04-21 |
| DE3313816A1 (de) | 1984-10-18 |
| ZA842775B (en) | 1984-11-28 |
| DK120084A (da) | 1984-10-17 |
| EP0122584A3 (de) | 1985-08-28 |
| GR81980B (enrdf_load_stackoverflow) | 1984-12-12 |
| KR910004300B1 (ko) | 1991-06-25 |
| ES8501768A1 (es) | 1984-12-01 |
| AU2685884A (en) | 1984-10-18 |
| EP0122584A2 (de) | 1984-10-24 |
| PT78419B (de) | 1986-06-02 |
| PT78419A (de) | 1984-05-01 |
| KR840008371A (ko) | 1984-12-14 |
| JPS59199689A (ja) | 1984-11-12 |
| GR81981B (enrdf_load_stackoverflow) | 1984-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4329453A (en) | Cephalosporin antibiotic | |
| EP2062581A1 (en) | The antibiotics composition comprising beta-lactam antibiotics and ionic chelating agents | |
| DK166541B1 (da) | Fremgangsmaade til isolering af isosilybinfrit silibinin | |
| NO323815B1 (no) | Karbapenemantibiotikum,farmasoytisk preparat omfattende dette og fremgangsmate for stabilisering av karbapenemantibiotikum. | |
| US4624948A (en) | Crystalline modification of ceftazidim | |
| CA1326486C (en) | Potassium clavulanate | |
| CA1243297A (en) | Crystalline modification of ceftazidim | |
| IE50269B1 (en) | Improvements in or relating to a cephalosporin antibiotic | |
| US3351527A (en) | Stabilized benzathine penicillin compositions | |
| CA1231896A (en) | Stable antibacterial lyophilizate | |
| US3928592A (en) | Antibiotic pharmaceutical compositions | |
| ES2008951A6 (es) | Un procedimiento para preparar una composicion antibiotica de amplio espectro que contiene una combinacion de un zwitterion de cefalosporina liofilizado o precipitado y una sal. | |
| US3297692A (en) | 7-alkylmercaptoacetamidocephalosporanic acid | |
| US5288861A (en) | Potassium clavulanate in rosette form | |
| Acred | Therapeutic and kinetic properties of ceftazidime in animals | |
| CA1239390A (en) | Cefonicid monosodium salt | |
| EP0354757A3 (en) | Cephalosporins and homologous compounds, process for their preparation and pharmaceutical compositions containing them | |
| EP0381915B1 (en) | Process for preparing alkali metal salts of 3,7-substituted 7-aminocephalosporanic acid derivatives. | |
| JPS5936616A (ja) | セフアロスポリン誘導体の安定な医薬組成物 | |
| GB1562802A (en) | Pharmaceutical compositions containing containing clavulanic acid | |
| CN110585201A (zh) | 抗菌剂与β-内酰胺酶抑制剂组合物及其应用 | |
| GB1334079A (en) | 7-alpha-2,6-dihalo-4-pyridylthio acetamido cephalosporanic acids and derivatives thereof | |
| JPS57136586A (en) | Cephalosporin derivative and its preparation | |
| JPS5467036A (en) | Cephalosporin preparation for oral administration | |
| JPS5625188A (en) | 7alpha-methoxycephalosporin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |